The Athenex Board of Directors is composed of carefully selected professionals who bring a wealth of governance and global corporate experience.


johnsonJohnson Y.N. Lau, MBBS, MD, FRCP

Chief Executive Officer and Board Chairman

Johnson is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in US history. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals. Prior, Johnson served as the Senior Director of Antiviral Therapy at Schering-Plough. Johnson has contributed more than 250 scientific publications and editorials/reviews/chapters in peer reviewed scientific journals and has edited two books. He was a former Managing Director at Roth Capital Partners, a Director of the Board of Chelsea Therapeutics (CHTP), serving as the Chair of the Audit and Finance Committee as well as the Corporate Governance Committee, as well as other public and private companies. He is currently serving on the Board of Porton Fine Chemicals (Listed in Shenzhen Exchange: 300363), and private companies including Avalon Biomedical Management Limited, Avagenex Limited, Aiviva Corporation, and Hong Kong X-tech Startup platform (general partner and mentor). He is also an Executive Board Member of the charity Project Vision and is an honorary professor/adjunct professor of the University of Hong Kong and Hong Kong Polytechnic University and a member of the Advisory Board of the School of Biomedical Sciences of the Chinese University of Hong Kong. Johnson received his medical degree (MBBS) and medical doctorate degree (MD) from the University of Hong Kong. He is also a Fellow of the Royal College of Physicians. Johnson has served as the Chairman of the Board of Athenex since its inception and assumed the role of CEO in mid 2011.

kim-cKim Campbell, PC, CC, OBC, QC

Lead Independent Director
Canada’s Nineteenth Prime Minister

The Right Honourable Kim Campbell served as Canada’s nineteenth and first female Prime Minister in 1993. She previously held cabinet portfolios as Minister of Justice and Attorney General, Minister of State for Indian Affairs and Northern Development and Minister of National Defence and Minister of Veterans’ Affairs. She was the first woman to hold the Justice and Defence portfolios, and the first woman to be Defence Minister of a NATO country. Kim participated in major international meetings including the Commonwealth, NATO, the G-7 Summit and the United Nations General Assembly.

After her tenure as Prime Minister, Kim was a fellow at the Institute of Politics (Spring 1994) and the Joan Shorenstein Center for the Study of Press and Politics (1994-1995) at the Harvard Kennedy School of Government. She served as the Canadian Consul General in Los Angeles (1996-2000), then returned to Harvard to teach at the Center for Public Leadership at the Kennedy School (2001- 2004).

Kim is a founding member of the Club of Madrid, an organization of former heads of government and state who work to promote democratic values. She served as Secretary General (2004- 2006). She also has served as its Acting President in 2002, its Vice President in 2003-2004 and served on its Board of Directors from 2007-2011.

Kim is a member and chair emerita of the Council of Women World Leaders (1999-2003). The Council’s membership consists of women who hold or have held the office of President or Prime Minister. Kim is a member of the International Women’s Forum, a global organization of women of significant and diverse achievement. She served as its president (2003-2005) and was inducted into the IWF Hall of Fame in 2008.

Today, Kim devotes the majority of her time to serving as the founding principal of the new Peter Lougheed Leadership College at the University of Alberta. She is also a trustee of the International Center for the Study of Radicalisation and Political Violence (ICSR) at King’s College London. She is a member of the Pacific Council on International Policy, (the West Coast affiliate of the Council on Foreign Relations) and the Global Council of the Asia Society of New York. She is on the advisory board of Equal Voice and an honorary patron of Informed Opinions. She is also a senior advisor to the Crisis Group and an honorary board member of the Climate Action Reserve and previously served as a trustee of the Salk Institute for Biological Studies 2007-2010.

Michael Cannon

Retired Chief Scientific Officer and Executive VP – SICOR

Mr. Cannon has over forty years experience in the pharmaceutical industry. He worked for twenty years at SICOR, a Swiss-Italian API manufacturing company, in a variety of positions in manufacturing, quality and regulatory affairs before moving to business development. He was a member of the team that conducted the merger of SICOR with Gensia of San Diego in 1997. He served as a member of SICOR’s board and president of the biotech division until the company was sold to Teva in 2004. He is now a board member of Waterstone, a Chinese pharmaceutical company, as well as Osel and BioSentinel in the US.

manson_bioManson Fok, MBBS, FRCS, FCSHK, FHKAM

Chairman – Pedder Clinic
Dean of Faculty – Health Sciences, Macau University of Science and Technology

Manson is a successful medical doctor, entrepreneur and philanthropist. Manson is the Chairman of the Pedder Clinic, one of the largest private surgical practices in Hong Kong. He is also the Dean, Faculty of Health Sciences at Macau University of Science and Technology (MUST); Hospital Director of University Hospital at MUST; President of the Macau Healthcare Management and Promotion Association (MHMPA); Censor-in-Chief, World Chinese Doctors’ Association; Honorary Fellow, Chinese College of Surgeons; Committee member, The Council of Medical Affairs in Macau SAR, among many other leadership positions. Manson was awarded the 2014 Gusi Peace Prize in Humanitarianism for his remarkable contributions to medical education, healthcare delivery and cross-border biotechnology developments that act as a bridge within Asia and across continents. Since 2015, he was appointed as the CEO of the same Peace Prize Foundation to continue promoting peace, cooperation and healthcare development in Asia-Pacific regions. After receiving his medical degree (MBBS) from the University of Hong Kong in 1982, Manson was appointed faculty in the Surgical Unit of the University of Hong Kong. Manson has published many original research papers in high-ranking international medical journals and chapters in various academic books focusing on minimally invasive treatment for esophageal surgery. Manson is actively advising Athenex to develop and execute on its Asian Business Strategy.

Sheldon Trainor-Degirolamo

Founder and Managing Director – PacBridge Capital Partners (HK) Limited

Mr. Trainor-Degirolamo is the Founder and Managing Director of PacBridge Capital Partners (HK) Limited, a principal investment and advisory firm based in Hong Kong, which he founded in 2009. Prior to establishing PacBridge, Mr. Trainor-Degirolamo spent more than 20 years in roles of increasing responsibility in the financial services industry, including with Credit Suisse Australia, Morgan Stanley Asia and as Head of Investment Banking for Asia and as Vice Chairman of Merrill Lynch Asia. Since 2012, he has also served as an Executive Director of Macau Legend Development Company Ltd., a company listed on the Hong Kong Stock Exchange. Mr. Trainor-Degirolamo received his Bachelor of Commerce from the University of British Columbia.

jinnwu2Jinn Wu, PhD

Retired Chief Executive Officer – XenoBiotic Laboratories and XBL-China

Jinn is the Founder and President of XenoBiotic Laboratories, Inc. (XBL) in Plainsboro, New Jersey, and XBL- China in Nanjing, China. Both are contract research organizations that provide an extensive array of clinical and preclinical research services to the life sciences, biotechnology and pharmaceutical industries. Jinn earned a PhD in Natural Products and Medicinal Chemistry from the College of Pharmacy, The Ohio State University, and spent 7 years as a research leader at FMC Corporation in Princeton, NJ, and made numerous contributions in new products research and development before starting XBL. He has extensive knowledge and experience in new drug and product R&D. He is an Adjunct Professor at the University of Medicine and Dentistry of New Jersey (UMDNJ at Rutgers) since 2006, was a member of the Advisory Committee for Dean’s Council and is a member of the College of Pharmacy, The Ohio State University (2007-2013). He is also an Adjunct Professor at The Hong Kong Polytechnic University (2015 – present). He holds professional membership of the American Association of Pharmaceutical Scientists (AAPS), the International Society for the Study of Xenobiotics (ISSX), the American Society of Pharmacognosy (ASP) and the American Chemical Society (ACS). He has served as Chief Scientific Officer and Strategic Scientific Advisor at WuXi AppTec, Lab Testing Division. He has also served on the Board of Directors of Ardent Pharmaceuticals and Enhance Biotech, Inc.
Jinn has been very active in public services including many non-profit scientific associations and charitable organizations. Dr. Wu was the recipient of The Jack L. Beal Postbaccalaureate Award (1994), College of Pharmacy, The Ohio State University and the recipient of the Distinguish Alumni Award (2007) from The National Taiwan University. He is also the Keynote Speaker for the Research Day at the College of Pharmacy, The Ohio State University, April 7, 2015.

Song-Yi_Zhang-500x500Song-Yi Zhang, JD

Founder and Chairman – Mandra Capital

Song-Yi is the founder of Mandra Capital, an investment holding company focused on early stage opportunities in internet, life science, materials and technologies. Song-Yi has more than twenty years of investment banking and direct investment experience. In addition to his responsibilities at Mandra Capital, Song-Yi serves as a director of SINA Corporation, a company listed on the Nasdaq Stock Market, and an independent non-executive director of China Long Yuan Electric Power Group Corp. and China Renewal Energy Investment Limited, each a company listed on Hong Kong Stock Exchange. Prior to founding Mandra Capital, Song-Yi served as a Managing Director of Asia Merger, Acquisition and Divestiture Group, and the co-Head of Asia Resources and Infrastructure Group of Morgan Stanley, and a Senior Associate of Milbank, Tweed, Hadley & McCloy LLP. Song-Yi holds a Juris Doctor degree from Yale University.

James_ZukinJames Zukin, MBA

Co-Founder – Houlihan Lokey

Mr. Zukin is the Co-Founder of Houlihan Lokey. Mr. Zukin has served on the faculty of various World Bank, IFC, and IMF conferences. He serves as a delegate to the Paris Club meetings involving the private sector. He has also delivered keynote speeches at the NAST and TIE conferences. In 2004, he formed Houlihan Lokey’s Sovereign Advisory Services practice, whose clients include Antigua & Barbuda, Belize, the Dominican Republic, Liberia, the Republic of Iraq and the Russian Federation. Mr. Zukin often presents on Chinese M&A and restructuring issues to various Chinese officials, including the China Securities Regulatory Commission (CSRC), the Chinese Banking Regulatory Commission (CBRC) and the State-owned Assets Supervision and Administration Commission of the State Council (SASAC). He frequently speaks at business conferences in the United States and Asia on M&A, financial restructuring and shareholder liquidity, among other topics. He has delivered keynote addresses at the UCLA Anderson School of Management/Wilbur K. Woo Greater China Business Conference and also at Indianapolis University for their “U.S.-China Business Cooperation Conference” in Bloomington, Indiana. Mr. Zukin earned a B.A. with honors in economics and English (poetry) from the University of California at Berkeley and an MBA from Harvard Business School.